Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus

Gene Therapy

Volumn 15, Issue 20, 2008, Pages 1361-1371

  Foloppe, J ^a   Kintz, J ^a   Futin, N ^a   Findeli, A ^a   Cordier, P ^a   Schlesinger, Y ^a   Hoffmann, C ^a   Tosch, C ^a   Balloul, J M ^a   Erbs, P ^a  

^a TRANSGENE S A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; FUSION PROTEIN FCU1; ONCOLYTIC VIRUS; ONCOPROTEIN; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER GENE THERAPY; CANCER INHIBITION; COLON CANCER; COLORECTAL TUMOR; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE DELETION; GENE TARGETING; HUMAN; HUMAN CELL; LIVER METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUICIDE GENE THERAPY; TUMOR VOLUME; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CYTOSINE DEAMINASE; FLUCYTOSINE; GENE TARGETING; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; INJECTIONS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; PENTOSYLTRANSFERASES; PRODRUGS; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; VACCINIA VIRUS; VIRUS REPLICATION;

MUS MUSCULUS; VACCINIA VIRUS;

EID: 53649094575     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.82     Document Type: Article

References (50)

1. Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353: 391-399.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007; 57: 43-66.
3. Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med 2005; 56: 139-156.
4. Mayer-Kuckuk P, Banerjee D, Kemeny N, Fong Y, Bertino JR. Molecular therapies for colorectal cancer metastatic to the liver. Mol Ther 2002; 5: 492-500.
5. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047.
6. Kohne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP et al. European Organisation for Research and Treatment of Cancer Gastrointestinal Group. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-4865.
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
8. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
9. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-338.
10. Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL et al Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13: 15-63.
11. Gene therapy clinical trials world wide. J Gene Med. Available from: www.wiley.co.uk/genmed/clinical.
12. Kievit E, Bershad E, Ng E, Sethna P, Dev I, Lawrence TS et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/ prodrug gene therapy in colon cancer xenografts. Cancer Res 1999; 59: 1417-1421.
13. Hamstra DA, Rice DJ, Fahmy S, Ross BD, Rehemtulla A. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther 1999; 10: 1993-2003.
14. Tiraby M, Cazaux C, Baron M, Drocourt D, Reynes JP, Tiraby G. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 1998; 167: 41-49.
15. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F et al. qIn vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-3822.
16. Erbs P, Findeli A, Kintz J, Cordier P, Hoffmann C, Geist M et al. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther 2008; 15: 18-28.
17. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491-502.
18. Kirn DH, McCormick F. Replicating viruses as selective cancer therapeutics. Mol Med Today 1996; 2: 519-527.
19. Martuza RL. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 2000; 105: 841-846.
20. Figova K, Hrabeta J, Eckschlager T. Reovirus - possible therapy of cancer. Neoplasma 2006; 53: 457-462.
21. Shen Y, Nemunaitis J. Fighting cancer with vaccinia virus: Teaching new tricks to an old dog. Mol Ther 2005; 11: 180-195.
22. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-6079.
23. Sze DY, Freeman SM, Slonim SM, Samuels SL, Andrews JC, Hicks M et al Dr Gary J Becker Young Investigator Award: Intraarterial adenovirus for metastatic gastrointestinal cancer: Activity, radiographic response, and survival. J Vasc Interv Radiol 2003; 14: 279-290.
24. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985; 317: 813-815.
25. Acres B, Dott K, Stefani L, Kieny MP. Directed cytokine expression in tumour cells in vivo using recombinant vaccinia virus. Ther Immunol 1994; 1: 17-23.
26. Puhlmann M, Gnant M, Brown CK, Alexander Jr HR, Bartlett DL. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther 1999; 10: 649-657.
27. Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander Jr HR et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000; 7: 66-73.
28. Taylor G, Stott EJ, Wertz G, Ball A. Comparison of the virulence of wild-type thymidine kinase (tk)-deficient and tk+ phenotypes of vaccinia virus recombinants after intranasal inoculation of mice. J Gen Virol 1991; 72: 125-130.
29. Merchlinsky M, Moss B. Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: Recombination-independent selectable cloning vectors. Virology 1992; 190: 522-526.
30. Hung CF, Tsai YC, He L, Coukos G, Fodor I, Qin L et al. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Therapy 2007; 14: 20-29.
31. Gnant MF, Noll LA, Irvine KR, Puhlmann M, Terrill RE, Alexander Jr HR et al. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J Natl Cancer Inst 1999; 91: 1744-1750.
32. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-1835.
33. Matono S, Tanaka T, Sueyoshi S, Yamana H, Fujita H, Shirouzu K. Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer. Int J Oncol 2003; 23: 1309-1315.
34. McCart JA, Puhlmann M, Lee J, Hu Y, Libutti SK, Alexander Jr HR et al Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Therapy 2000; 7: 1217-1223.
35. Nakamura H, Mullen JT, Chandrasekhar S, Pawlik TM, Yoon SS, Tanabe KK. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001; 61: 5447-5452.
36. Bernt KM, Steinwaerder DS, Ni S, Li ZY, Roffler SR, Lieber A. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res 2002; 62: 6089-6098.
37. Schepelmann S, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I et al. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res 2007; 67: 4949-4955.
38. Eisenberg DP, Adusumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan MK et al. 5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg 2005; 9: 1068-1077.
39. Karupiah G, Coupar B, Ramshaw I, Boyle D, Blanden R, Andrew M. Vaccinia virus-mediated damage of murine ovaries and protection by virus-expressed interleukin-2. Immunol Cell Biol 1990; 68: 325-333.
40. Gnant MF, Puhlmann M, Bartlett DL, Alexander Jr HR. Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases. Ann Surg 1999; 230: 352-360.
41. Naik AM, Chalikonda S, McCart JA, Xu H, Guo ZS, Langham G et al. Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates. Hum Gene Ther 2006; 17: 31-45.
42. Neeman M, Abramovitch R, Schiffenbauer YS, Tempel C. Regulation of angiogenesis by hypoxic stress: From solid tumours to the ovarian follicle. Int J Exp Pathol 1997; 78: 57-70.
43. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI et al. NYVAC: A highly attenuated strain of vaccinia virus. Virology 1992; 188: 217-232.
44. Kretzschmar M, Wallinga J, Teunis P, Xing S, Mikolajczyk R. Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med 2006; 3: 1341-1351.
45. Kieny MP, Lathe R, Drillien R, Spehner D, Skory S, Schmitt D et al Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984; 312: 163-166.
46. Paoletti E. Applications of pox virus vectors to vaccination: An update. Proc Natl Acad Sci USA 1996; 93: 11349-11353.
47. Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1988; 67: 31-40.
48. Greene GL, Fitch FW, Jensen EV. Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors. Proc Natl Acad Sci USA 1980; 77: 157-161.
49. McBee P, Petraiuolo W, Katoh A. Inhibition of liver metastases in nude mice by the combined action of 5-fluorouracil and interferon. Anticancer Drugs 1990; 1: 165-170.
50. Sova P, Ren XW, Ni S, Bernt KM, Mi J, Kiviat N et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004; 9: 496-509.